NSP1 hoSPIs included the nonopioid sigma receptor SIGMAR1, which was recently identified as host-dependency factor for SARS-CoV-2 infection and represents a potential drug target for treatment of COVID-19 [61, 62]. This evidence concerns the gene SIGMAR1 and COVID-19.